Flaxseed modulates inflammatory and oxidative stress biomarkers in cystic fibrosis: a pilot study

BMC Complementary and Alternative Medicine

Research Article

Melpo Christofidou-Solomidou¹  John A Lawson¹  Ralph A Pietrofesa²  Denis Hadjiliadis²  Jason B Turowski² 

[1] Department of Pharmacology, University of Pennsylvania Perelman School of Medicine, 19104, Philadelphia, PA, USA;Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, 835W Gates Building, 3600, Spruce Street, 19104, Philadelphia, PA, USA;

关键词: Antioxidant;    Biomarker;    Cystic fibrosis;    Cytokine;    Enterodiol;    Enterolactone;    Flaxseed;    Inflammation;    Lignan;    Secoisolariciresinol diglucoside;   

DOI  :  10.1186/s12906-015-0651-2

 received in 2014-09-12, accepted in 2015-04-15,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundCystic fibrosis (CF) leads to advanced lung disease despite aggressive care. Persistent inflammation and oxidative stress contribute to exacerbations and disease progression. Flaxseed (FS), a dietary botanical supplement with high fiber, lignan phenolics, and omega-3 fatty acids has anti-inflammatory and antioxidant properties in murine models of acute and chronic lung injury. This pilot study was designed to determine whether CF patients could tolerate FS, evaluate circulating FS metabolites, and study biomarkers of lung damage, as a prelude to studying clinical outcomes.Methods10 CF patients and 5 healthy volunteers consumed 40 g of FS daily for 4 weeks with safety and tolerability being assessed. Urine was evaluated for systemic oxidative stress and plasma for FS metabolites (enterolignans) and cytokine levels. Buccal swabs were analyzed for gene expression of Nrf2-regulated antioxidant enzymes including Heme Oxygenase-1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1 (NQO1).ResultsAll subjects completed the study without serious adverse events. Plasma levels of enterolignans were detectable in both healthy controls and CF volunteers. CF patients were stratified based on plasma enterolignan levels after 2 weeks of FS administration into high- (174 to 535 nM ED and 232 to 1841 nM EL) and low- (0 to 32 nM ED and 0 to 40 nM EL) plasma lignan cohorts. The low enterolignan level cohort experienced a statistically significant drop in urinary inflammatory IsoP and plasma TNFα levels, while demonstrating higher average NQO1 mRNA levels in buccal epithelium compared to high-lignan patients.ConclusionsThis pilot study demonstrated that FS is tolerated by CF patients. FS metabolites could be detected in the plasma. Future studies will assess appropriate dosing and target populations for FS, while exploring clinical outcomes.Trial registrationClinicalTrials.gov identifier: NCT02014181.

【 授权许可】

Unknown   
© Turowski et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.